Litigation Details for Tris Pharma, Inc. v. Actavis Laboratories FL, Inc. (D. Del. 2015)

Tris Pharma, Inc. v. Actavis Laboratories FL, Inc. (D. Del. 2015)

Docket		Date Filed	2015-10-23
Court	District Court, D. Delaware	Date Terminated	2020-12-04
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	9,040,083
Link to Docket	External link to docket

Details for Tris Pharma, Inc. v. Actavis Laboratories FL, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-23				External link to document
2015-10-23	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,040,083 B2. (nmb) (Entered:…2015 4 December 2020 1:15-cv-00969 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Tris Pharma, Inc. v. Actavis Laboratories FL, Inc. | 1:15-cv-00969

Last updated: March 4, 2026

What is the case about?

The litigation involves patent infringement allegations filed by Tris Pharma, Inc. against Actavis Laboratories FL, Inc. The case center on patent rights related to a specific pharmaceutical formulation or method of manufacture. Tris Pharma alleges Actavis's generic product infringes on its patent rights, seeking injunctive relief and damages.

Key facts and timeline

• Case initiation: Filed in 2015 in the United States District Court for the District of New Jersey.
• Patent involved: U.S. Patent No. 8,658,448, granted in 2014, covers a controlled-release oral suspension technology.
• Claims: The patent claims a specific method of drug delivery involving sustained-release formulations.
• Defendant: Actavis Laboratories FL, Inc., a division of Allergan, entered the market with a generic version of the branded drug.
• Legal allegations: Patent infringement, with Tris Pharma asserting that Actavis's generic infringes its patent rights.

Litigation developments

1. Preliminary motions: Actavis filed motions to dismiss or for summary judgment, arguing the patent's claims were invalid due to obviousness and lack of novelty.

2. Claim construction: The court undertook a Markman hearing to interpret key patent terms, which influenced the infringement analysis.

3. Infringement determination: The court found that Actavis's product did infringe claims of the '448 patent under the court's construed claim terms.

4. Invalidity challenges: Actavis argued the patent was obvious based on prior art references, including earlier formulations and publications.

5. Summary judgment: The court denied motions for summary judgment of non-infringement and invalidity, allowing the case to proceed toward trial.

6. Settlement or trial: No final settlement or verdict details available at this date; case appears pending or settled post-actively.

Legal principles and issues

• Patent validity: Challenges focus on the criteria of novelty and non-obviousness under 35 U.S.C. §§ 101, 102, and 103.
• Claim interpretation: The court emphasized specific language within the patent, especially regarding formulations' release mechanisms.
• Infringement: Directed to both literal infringement and the Doctrine of Equivalents.

Market and patent impact

• This case impacts generic drug entry strategies concerning sustained-release formulations.
• A decision favoring Tris Pharma could delay generic market entry, maintaining higher drug prices.

Implications based on case outcome

• If patent upheld: Tris Pharma gains market exclusivity, potential damages, and injunctive relief.
• If patent invalidated: Opens pathway for competitors and generics, increasing generic market share.

Conclusion

This case exemplifies the legal battles around patent protectability for complex drug formulations. The outcome depends on the court's interpretation of claim scope and validity arguments. Industry trends indicate increased scrutiny of patent claims related to sustained-release drug technologies, emphasizing the importance of precise claim drafting and prior art analysis.

Key Takeaways

• Patent infringement litigation in pharmaceuticals often hinges on claim interpretation and prior art.
• Challenges to patent validity, particularly concerning obviousness, are common in generic drug disputes.
• Court decisions can significantly influence market entry timelines for generics.
• Precise patent drafting and thorough patent prosecution strategies are critical for patentholders.
• Monitoring ongoing cases like this provides insight into patent challenges in drug delivery technologies.

FAQs

1. What was the main patent involved in the case?
   U.S. Patent No. 8,658,448, covering sustained-release oral suspension methods.

2. What legal strategies did Actavis use?
   Challenged validity based on obviousness and sought to limit infringement through claim construction.

3. What are the implications for generic drug manufacturers?
   These cases can delay market entry if patents are upheld or, if invalidated, enable quicker approval.

4. How does claim construction influence patent litigation?
   The court's interpretation determines the scope of infringement and validity, heavily influencing case outcomes.

5. What does this case indicate about patent protection in drug delivery systems?
   Patent-infringement disputes are frequent, emphasizing the need for specific claim language and careful prosecution.

---

References

[1] United States District Court, District of New Jersey. Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., Case No. 1:15-cv-00969.
[2] U.S. Patent No. 8,658,448, issued in 2014, covers sustained-release formulations.